SML0613

Rofecoxib

≥98% (HPLC)

• Synonym(e): 4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone
• Empirische Formel (Hill-System): C₁₇H₁₄O₄S
• CAS-Nummer: 162011-90-7
• Molekulargewicht: 314.36
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 5 mg/mL, clear (warmed)
• storage temp.: 2-8°C
• SMILES string: [S](=O)(=O)(C)c1ccc(cc1)C2=C(C(=O)OC2)c3ccccc3
• InChI: 1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
• InChI key: RZJQGNCSTQAWON-UHFFFAOYSA-N

Beschreibung

Application

Rofecoxib has been used in high performance bioaffinity chromatography.

Biochem/physiol Actions

Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with >800-fold COX-2 selectivity in CHO cells expressing human COX-1 and COX-2.

Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor.

Rofecoxib is derived from furanone and has the ability to cross human placenta. Along with anti-inflammatory action, it possesses analgesic and antipyretic properties. Cytosolic hepatic enzymes are responsible for the metabolism of rofecoxib. It is known to cause oligohydramnios and ductus arteriosus constrictions. Rofecoxib inhibits the action of CYP1A2 (cytochrome P450 family 1 subfamily A member 2). It might be associated with aseptic meningitis. Rofecoxib is known to ameliorate the risk of colorectal adenoma, but might contribute to toxicity.

Sicherheitshinweise

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable